Molecular Formula	C9H14N5O4P
Molecular Weight	287.21
Structure
State	solid
Clearance	The clearance of tenofovir is highly dependent on the patient renal stage and hence the clearance rate in patients with renal impairment is reported to be of 134 ml/min while in patients with normal function the clearance rate can be of 210 ml/min.[A178525]
Volume of distribution	Accumulation of tenofovir in plasma is related to the presence of nephrotoxic effects.[A178060] It is reported that tenofovir presents a volume of distribution of 0.813 L/kg.[A16539]
Route of elimination	Tenofovir is eliminated in the urine by tubular secretion and glomerular filtration. The elimination of this compound is driven by the activity of the human organic anion transporters 1 and 3 and its secretion is mainly ruled by the activity of the multidrug resistance-associated protein 4.[A178060]
Protein binding	Tenofovir is minimally bound to plasma proteins and only about 7.2% of the administered dose is found in the bound state.[A16539]
Half life	The reported half-life of tenofovir is of 32 hours.[A178231]
Absorption	Tenofovir as the active moiety presents a very low bioavailability when orally administered. Hence, the administration of this active agent is required to be under its two prodrug forms, [tenofovir disoproxil] and [tenofovir alafenamide]. This reduced absorption is suggested to be related to the presence of two negative charges among its structure. This negative charge limits its cellular penetration, and its passive diffusion across cellular membranes and intestinal mucosa hindering its availability for oral administration.[A178060] Intravenous tenofovir has been shown to produce a maximum plasma concentration of 2500 ng/ml with an AUC of 4800 ng.h/ml.[A18473]
Trade names	Viread
Description	antiviral; nucleotide analog reverse-transcriptase inhibitor (NtRTI); inhibits viral reverse transcriptase; tenofovir is an acyclic analog of deoxyadenosine 5'-monophosphate (d-AMP);

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
ELECTRON TRANSPORT CHAIN						decrease		52
MITOCHONDRIAL DNA METABOLIC PROCESS								194

Target	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
DNA polymerase gamma								194

Pictogram	Signal	Statements	Precautionary Statement Codes
	Danger	Aggregated GHS information provided by 2 companies from 1 notifications to the ECHA C&L Inventory. H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.	P280, P305+P351+P338, and P310; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Chronic hepatitis B

Foetor hepaticus

Hepatitis B e antigen positive

Hepatocellular injury

Infection

Liver disorder

Fatigue (0.08)

Upper respiratory tract infection (0.05)

Abdominal pain

Asthenia

Back pain

Body temperature increased

Chest pain

Decreased appetite

Depression

Dermatitis

Diarrhoea

Dizziness

Dyspepsia

Fasting

Flatulence

Gastrointestinal pain

Glycosuria

Headache

Hyperhidrosis

Insomnia

Musculoskeletal discomfort

Myalgia

Nausea

Neuropathy peripheral

Pain

Pneumonia

Rash

Vomiting

Weight decreased

(((1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid	(R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID	(R)-(+)-9-[2-Phosphonylmethoxyethyl]adenine
(R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid	(R)-9-(2-Phosphonomethoxypropyl)adenine	(R)-9-(2-Phosphonoylmethoxypropyl)adenine
(R)-9-(Phosphonomethoxypropyl)adenine	(R)-9-[2-(Phosphonomethoxy)propyl]adenine	(R)-9-[2-(phosphonomethoxy) propyl] adenine
(R)-PMPA	(R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid	({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
114611-EP2272516A2	114611-EP2298783A1	127T206
147127-20-6	24230-EP2298783A1	24230-EP2314590A1
9-PMPA	9-[(R)-2-(phosphonomethoxy)propyl]adenine	AB0017664
AB01274787-01	AB01274787_02	AB01274787_03
ABP000917	AC-760	ACN-029240
AK-33334	AKOS015856701	AKOS015894941
AM20090678	API0015388	AX8018435
BCPP000049	BG0625	BR-33334
BRD-K15891719-001-02-8	C17407	CHEBI:63625
CHEMBL483	CP-558	CS-1609
CTK4C5270	D,L-Tenofovir	DTXSID9040132
EC 604-571-2	FT-0601652	GNA & Tenofovir
GS 1275	GS 1278	GS-1278
HHA & Tenofovir	HMS3264H05	HY-13910
J90012	KS-5021	KSC525E7B
PMPA	PMPA gel	PMPA-(R)
Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-	Phosphonic acid, ((2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-, (R)-	Phosphonic acid, P-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-	Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)	Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
PubChem9452	Q-201787	Q155954
S-2389	SC-01187	SCHEMBL39724
SGOIRFVFHAKUTI-ZCFIWIBFSA-N	SR-01000883934	SR-01000883934-1
ST24033314	TFV gel	TR-035738
Tenofovir	Tenofovir (Viread)	Tenofovir [USAN:INN:BAN]
Tenofovir gel	Tenofovir gel (GS-1278)	Tenofovir, >=98% (HPLC)
Tenofovir,TDF,PMPA/	Truvada	UNII-W4HFE001U5
Viread (prodrug for Tenofovir)	W4HFE001U5	ZINC1543475
[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methylphosphonic acid	[2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY]METHYLPHOSPHONIC ACID	[[(1R)-2(6-Amino-9H-Purin-9-Yl)-1-Methylethoxy]Methyl]Phosphonic Acid
anh. tenofovir	anhydrous tenofovir	tenofovir (anh.)
tenofovir (anhydrous)	{[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl}phosphonic acid

DrugBank Name	Tenofovir
DrugBank	DB14126
CAS Number	107021-12-5, 147127-20-6, 206184-49-8
PubChem Compound	464205
KEGG Compound ID	C17407
ChEBI	63625
PharmGKB	PA10204
ChemSpider	408154
Wikipedia	Tenofovir_disoproxil
HET	TFO